ImageneBio (NASDAQ:IMA – Get Free Report) and AC Immune (NASDAQ:ACIU – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Earnings & Valuation
This table compares ImageneBio and AC Immune”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImageneBio | $800,000.00 | 57.32 | -$45.35 million | ($4.58) | -0.88 |
| AC Immune | $4.31 million | 56.43 | -$85.03 million | ($0.54) | -4.43 |
ImageneBio has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ImageneBio and AC Immune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImageneBio | N/A | -38.99% | -34.84% |
| AC Immune | -245.32% | -100.17% | -28.36% |
Insider & Institutional Ownership
75.0% of ImageneBio shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings for ImageneBio and AC Immune, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImageneBio | 2 | 0 | 1 | 1 | 2.25 |
| AC Immune | 1 | 0 | 3 | 1 | 2.80 |
ImageneBio presently has a consensus price target of $29.00, suggesting a potential upside of 617.82%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 213.81%. Given ImageneBio’s higher possible upside, research analysts clearly believe ImageneBio is more favorable than AC Immune.
Risk and Volatility
ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.
About ImageneBio
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
